Altimmune, Inc.
ALT
$3.31
-$0.06-1.64%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 15.32% | -15.89% | |||
| Gross Profit | -15.32% | 15.78% | |||
| SG&A Expenses | -5.94% | -23.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.05% | -18.62% | |||
| Operating Income | -8.05% | 18.54% | |||
| Income Before Tax | -1.16% | 17.53% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1.16% | 17.53% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.16% | 17.53% | |||
| EBIT | -8.05% | 18.54% | |||
| EBITDA | -8.06% | 18.55% | |||
| EPS Basic | 32.10% | 33.32% | |||
| Normalized Basic EPS | 32.36% | 35.43% | |||
| EPS Diluted | 32.10% | 33.32% | |||
| Normalized Diluted EPS | 32.36% | 35.43% | |||
| Average Basic Shares Outstanding | 49.00% | 23.70% | |||
| Average Diluted Shares Outstanding | 49.00% | 23.70% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||